देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
NIFEDIPINE
JAMP PHARMA CORPORATION
C08CA05
NIFEDIPINE
60MG
TABLET (EXTENDED-RELEASE)
NIFEDIPINE 60MG
ORAL
15G/50G
Prescription
DIHYDROPYRIDINES
Active ingredient group (AIG) number: 0115253005; AHFS:
APPROVED
2021-01-28
JAMP Nifedipine ER 1 PRODUCT MONOGRAPH PR JAMP NIFEDIPINE ER Nifedipine Extended Release Tablets USP 60 mg Antianginal/Antihypertensive Agent JAMP Pharma Corporation 1310 rue Nobel Boucherville, Québec J4B 5H3 Date of Revision: January 27, 2021 Submission Control No.: 247275 JAMP Nifedipine ER 2 TABLE OF CONTENTS PART I: HEALTH PROFESSION-AL INFORMATION ................................................................ 3 SUMMARY PRODUCT INFORMATION .................................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................................... 3 CONTRAINDICATIONS ................................................................................................................ 4 WARNINGS AND PRECAUTIONS .............................................................................................. 4 ADVERSE REACTIONS ................................................................................................................. 8 DRUG INTERACTIONS ............................................................................................................... 12 DOSAGE AND ADMINISTRATION ........................................................................................... 17 OVERDOSAGE .............................................................................................................................. 18 ACTION AND CLINICAL PHARMACOLOGY ....................................................................... 19 STORAGE AND STABILITY ....................................................................................................... 21 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................................ 21 PART II: SCIENTIFIC INFORMATION ....................................................................................... 23 PHARMACEUTICAL INFORMATION ..................................................................................... 23 CLINICAL TRIALS ........... पूरा दस्तावेज़ पढ़ें